Continuous Composites Secures Additional Funding to Advance High-Temperature Materials with CF3D® Technology
COEUR D'ALENE, Idaho, June 9, 2025 /PRNewswire/ -- Continuous Composites (CCI) has been awarded multi-million-dollar funding from the U.S. Air Force as part of a multi-year contract to advance the development of high-performance materials using CF3D® technology. This funding is divided into two phases:
The first phase, currently underway, focuses on establishing baseline material properties and a performance validation campaign to benchmark CF3D-produced components against traditional manufacturing methods, such as those used for materials like Carbon-Carbon.
The second phase of the funding will support the expansion of this work, enabling full-scale component production and flight testing. This phase will allow CCI to refine production processes, conduct additional testing, and further advance CF3D's capabilities for high-temperature applications.
CF3D (Continuous Fiber 3D) technology enables the automated manufacturing of continuous fiber composites in near-net shapes, offering precise control over fiber orientation and geometry. This capability facilitates the scalable production of complex parts with enhanced design flexibility and the ability to meet the high-performance requirements of high-temperature applications.
About Continuous CompositesContinuous Composites is redefining composite manufacturing with CF3D, its patented Continuous Fiber technology. By integrating advanced materials fiber steering and automated manufacturing, CF3D enables the production of lightweight, high-performance structures with unmatched precision and scalability. This innovative approach transforms how complex components are made, unlocking new possibilities across aerospace, defense, and UAV sectors.
Media ContactLiz SchmittouDirector of Marketing, Continuous Compositesmedia@cf3d.comwww.continuouscomposites.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/continuous-composites-secures-additional-funding-to-advance-high-temperature-materials-with-cf3d-technology-302475572.html
SOURCE Continuous Composites
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
37 minutes ago
- Associated Press
Dark Matter Technologies achieves UCDP integration, driving appraisal innovation
- New integration enables appraisal report submission to the GSEs with enhanced data fields, ZIP file support and modernized infrastructure - JACKSONVILLE, Fla., July 1, 2025 (SEND2PRESS NEWSWIRE) — Dark Matter Technologies (Dark Matter®), an innovative leader in mortgage technology, today announced it has established an integration with Uniform Collateral Data Portal® (UCDP®), a single portal jointly maintained by Fannie Mae and Freddie Mac (the GSEs). This expansion positions Dark Matter as an early adopter of the technology needed to support the Uniform Appraisal Dataset (UAD) 3.6 and Forms Redesign initiative. The new integration enables submission of appraisal report data to the GSEs via UCDP, supporting lenders in the mandate to adopt new appraisal standards and signaling Dark Matter's readiness to meet the new initiative well in advance of lenders' required adoption. Innovations to work with this effort include both the Empower® and the ExchangeSM Network support for a brand-new appraisal report data file, ZIP file submissions, integrating six new data fields to enhance property detail and a streamlined process for extracting PDF and XML files. These capabilities allow Dark Matter to assist lenders in transitioning to new UAD 3.6, simplifying reporting across any residential property type. The new UAD 3.6 is available for GSE-approved lenders during the limited production period, which begins September 8, 2025, and is required for all appraisal reports submitted to UCDP on or after November 2, 2026. 'By proactively adapting to these industry-driven updates, Dark Matter is demonstrating its technological leadership and commitment to driving efficiency in the mortgage ecosystem,' said Stephanie Durflinger, chief product officer at Dark Matter. 'This achievement helps us better serve our lending partners and opens the door to broader capabilities in digital appraisal delivery.' About Dark Matter Technologies: Operating with the nimble nature of a startup and the disciplined maturity of one of the industry's leading providers, Dark Matter Technologies delivers powerful technology with unparalleled automation and relentless innovation to leading mortgage lenders, servicers and companies nationwide. For more information, visit Tags: @dmattertech #fintech #mortgage Logo link for media: NEWS SOURCE: Dark Matter Technologies ### MEDIA ONLY CONTACT: (not for publication online or in print) Elizabeth Schroeder Depth for Dark Matter Technologies (209) 774-6555 [email protected] ### Keywords: FinTech, Dark Matter Technologies, fintech, Uniform Collateral Data Portal, mortgage technology, Fannie Mae and Freddie Mac, JACKSONVILLE, Fla. This press release was issued on behalf of the news source (Dark Matter Technologies) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P127317 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Associated Press
37 minutes ago
- Associated Press
Bedsure Unveils Back-to-School Prime Day Deals to Help Students Sleep Better and Save More
The viral Amazon bedding brand, Bedsure, offers a wide selection of back-to-school essentials. NEW YORK, July 1, 2025 /PRNewswire/ -- As students prepare to head back to school, Bedsure, a leading online bedding brand, is participating in this year's Amazon Prime Day Sale to offer a selection of durable, cozy bedding products designed with comfort, style, and student budgets in mind. Their bedding collection features dorm-ready bedding essentials that help students feel at home—wherever they are. From July 8–11, Bedsure will offer exclusive Prime Day discounts on top-rated dorm essentials, including their Bed-in-a-Bag set, mattress toppers, and decorative throws. Whether students are moving into a dorm, apartment, or their first off-campus home, Bedsure's Prime Day sale is the perfect opportunity to stock up on cozy must-haves. 'We know that a good night's sleep is essential for academic success,' said Eric Lin, Chief Marketing Officer of Bedsure. 'Prime Day is the perfect time for students and parents to save big on back-to-school essentials. Our collection of bedding is all about helping students create a cozy, personalized space that supports both rest and productivity.' Prime Day Highlights Include: All deals will be available exclusively on Amazon during Prime Day. With thousands of 5-star reviews and a reputation for quality and comfort, Bedsure's products are a smart choice for students looking to sleep better and study smarter. For more information about Bedsure's Prime Day deals, visit About Bedsure Founded in 2016, Bedsure is a leading home textile brand with products sold to over 40 million customers worldwide. Bedsure has over 50 bestselling home products in 8 countries and has maintained a compound growth rate of 100% for five consecutive years. While Bedsure has grown into a global company with a diverse range of products to meet various customer needs, its focus on providing comfortable home products and everyday value remains unchanged. For more information, visit Bedsure's official website or Amazon shop Stay in touch with Bedsure on social media @bedsurehome. View original content to download multimedia: SOURCE Bedsure
Associated Press
37 minutes ago
- Associated Press
Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia
White Bear Lake, Minnesota--(Newsfile Corp. - July 1, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ('Envoy Medical'), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia. The Australian Patent Office has issued the following three patents to Envoy Medical Corporation: 'These latest patent issuances continue to expand the depth and breadth of our intellectual property and reflect our commitment to advancing hearing technology that is integrated into patients' lives,' said Brent Lucas, CEO of Envoy Medical. 'Our team remains focused on delivering differentiated solutions that move the industry forward and are designed to meet the real-world needs of people living with hearing loss.' Envoy Medical's fully implanted technologies are designed to eliminate external components and leverage the natural anatomy of the ear for sound detection, offering a fundamentally different experience from traditional hearing aids or partially implanted systems. For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit To be added to the Envoy Medical email distribution list, please email [email protected] with COCH in the subject line. About Envoy Medical, Inc. Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life. About the Fully Implanted Acclaim® Cochlear Implant We believe the fully implanted Acclaim Cochlear Implant ('Acclaim CI') is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician. The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use. About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI) The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing. *Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use. Important safety information for the Esteem FI-AMEI can be found at: Additional Information and Where to Find It Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as 'estimate,' 'plan,' 'project,' 'forecast,' 'intend,' 'will,' 'expect,' 'anticipate,' 'believe,' 'seek,' 'target' or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the ability to obtain additional patents and develop future products or product improvements, the Acclaim CI being the first to market fully implanted cochlear implant, the timing and results of approvals, site documents, logistics, activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled 'Risk Factors' and 'Cautionary Note Regarding Forward Looking Statements' in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical. ### Investor Contact: Phil Carlson KCSA Strategic Communications O: 212.896.1233 E: [email protected] SOURCE: Envoy Medical, Inc. To view the source version of this press release, please visit
